New Drug Approvals

Home » 2013 » July

Monthly Archives: July 2013

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

Paypal donate

Blog Stats

  • 1,563,567 hits

Flag and hits

Flag Counter

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 1,943 other followers

Follow New Drug Approvals on WordPress.com

Archives

Categories

Flag Counter

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 1,943 other followers

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARK PHARMACEUTICALS LTD, Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 29 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 29 year tenure till date Aug 2016, Around 30 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 9 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 25 Lakh plus views on dozen plus blogs, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 13 lakh plus views on New Drug Approvals Blog in 212 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc

Personal Links

Verified Services

View Full Profile →

Archives

Categories

Flag Counter

Gene Therapy for Melanoma: Progress and Perspectives


media/image1.jpeg

FIGURE 1.

http://www.intechopen.com/books/recent-advances-in-the-biology-therapy-and-management-of-melanoma/gene-therapy-for-melanoma-progress-and-perspectives

Schematic representation of the wild type counterpart of the typically used recombinant viral vectors. (A) Gammaretroviruses and (B) lentiviruses share similar structures, but differ greatly in their genomes and their impact on cellular function. Gag, pro, pol and env genes encode structural proteins of the capsid, protease, reverse transcriptase and envelope proteins, respectively. The additional lentiviral genes perform regulatory functions as well as alter cellular function. (C) The serotype 5 adenovirus has a protein capsid (non-enveloped) and a large, complex genome that encodes critical genes for viral replication (E1a, E1b) as well as structural and functional genes that regulate both viral and cellular activities.

 Introduction

Gene therapy, the therapeutic transfer of genetic information to a target cell, continues to be a promising alternative in the fight against cancer. In the case of melanoma, the use of an experimental treatment is justified since this disease is incurable in its advanced stages. Is gene therapy a viable option for the treatment of melanoma patients? In this chapter, we will attempt to answer this question by exploring the intersection between the technology of gene therapy and the biology of melanoma, a point at which opportunities for intervention are revealed.

Gene Therapy for Melanoma: Progress and Perspectives

Bryan E. Strauss1 and Eugenia Costanzi-Strauss2

[1] Cancer Institute of Sao Paulo, University of Sao Paulo School of Medicine, Brazil

[2] University of Sao Paulo, Biomedical Sciences Institute, Brazil

http://www.intechopen.com/books/recent-advances-in-the-biology-therapy-and-management-of-melanoma/gene-therapy-for-melanoma-progress-and-perspectives

 

 

 

……………….

Advertisements

Analysis Of Vical’s Allovectin-7: Best Results Ever In A Melanoma Phase 3 Trial


check this video

…………….

immunotherapy - cancer

Vical’s (VICL) Allovectin-7 is a pure immune therapy.(1) Which means it does not directly kill cancer cells, but activates the immune system to do so. Vical will soon announce A-7 phase 3 results in Melanoma, but the mechanism of action is not specific to Melanoma, and can be used in any solid tumor cancer.(2) For this reason, I expect that Allovectin-7 will become one of the best selling cancer drugs of all time.

http://seekingalpha.com/article/1584402-analysis-of-vicals-allovectin-7-best-results-ever-in-a-melanoma-phase-3-trial?source=google_news

Allovectin-7 is a substance that is being studied as a gene therapy agent in the treatment of cancer, such as malignant melanoma. It is a plasmid/lipid complex containing the DNA sequences encoding HLA-B7 and ß2 microglobulin – two components of major histocompatibility complex (MHC, class I). It increases the ability of the immune system to recognize cancer cells and kill them.

In 1999, FDA granted Allovectin-7 orphan drug designation for the treatment of invasive and metastatic melanoma.

  • Allovectin-7 entry in the public domain NCI Dictionary of Cancer Terms

 This article incorporates public domain material from the U.S. National Cancer Institute document “Dictionary of Cancer Terms”.

Vical’s Allovectin-7

Allovectin is a first-class DNA-based immunotherapeutic designed to stimulate both innate and adaptive immune responses in local tumors and distal metastases. The goal is to become a first-line treatment for Stage III and IV melanoma, where it is intended to provide improved efficacy, a better safety profile, and simple outpatient administration.

As last reported, the company is approaching completion of a Phase III registration trial versus chemotherapy in patients with metastatic melanoma. The reporting of end results has had numerous delays, but the results are now expected by Q3.

Outside of Allovectin, Vical has ten clinical trials ongoing, three of those independent and the rest in collaboration. Clearly, Vical is not totally dependent on this immunotherapy though it is the most advanced independent program in the company’s pipeline.

Vical has a market cap of $257M, so clearly a homerun therapy could send the stock soaring.

Pfizer second quarter earnings beat estimates


July 30 2013 | By Márcio Barra

Pfizer reported today their second-quarter profits, beating analysts’ estimates as it prepares to rearrange its business operations. Earnings excluding one-time items were 56 cents a share, compared with the 55 cents average estimated by Bloomberg and Thomson Reuters I/B/E/S. Net income rose more than fourfold to $14.1 billion, or $1.98 a share, from $3.25 billion, or 43 cents last year. Revenue however, fell 7% to $12.97 billion, compared with the $13.03 billion analysts estimated.

View original post 628 more words

Kiran Mazumdar-Shaw, chairman and managing director of Indian biopharma giant Biocon propels company to clock revenue worth $121 mn


Kiran Mazumdar-Shaw, chairman and managing director, Biocon.

Kiran Mazumdar Shaw: She has the odd passion—artwork, horses—but it’s Biocon that really gives her joy

What do our other billionairesses like to splurge on? Kiran’s abiding passion, apart from her work, are horses and paintings—she particularly enjoys collecting the works of Yusuf Arakkal and S.G. Vasudev. Sailoja confesses she loves Louis Vuitton purses and diamond and gold jewellery. “But I haven’t bought any great jewellery for two years now,” she says. Shobhana admits to a weakness for designer watches and bags, as well as light, trendy and stylish fashion jewellery which is not necessarily very expensive. Ekta loves dressing up—but of course her biggest pleasure comes from watching her audience ratings soar.

For most, making billions is not what drives them. Sulajja, who recently sold a 15 per cent stake in her company to Anil Ambani’s Reliance Capital, could be speaking for all of them when she sums up: “Neither me nor my family has been about money. That’s not how we relate to people either. I appreciate that I have certain comforts and don’t have to struggle as much as some for basics, but beyond that we’re just simple hard-working people.”


By Paromita Shastri with Charubala Annuncio, Archana Rai and Madhavi Tata

FROM

Kiran Mazumdar-Shaw thinks her training in brewing helped her found biotech company Biocon.

Kiran Mazumdar-Shaw is one of the richest women in India. She is the founder of Biocon, a biotech company and Asia’s largest insulin maker.

But the chairman and managing director attributes her success to her go-getting nature rather than entrepreneurial spirit.

Ms Mazumdar-Shaw originally trained to become a brewer in Australia, before returning to India to follow in her father’s footsteps as a brew-master.

But she struggled to find a job on her return and recalls the industry wasn’t ready for a strong female presence. “The brewing industry is a very, very male dominated industry” she says. “It’s a male bastion.”

Opportunity

She refused to be thwarted. “I really wanted to do something with my life,” she remembers. It was this rebellious streak that inspired her to start her own company, although she admits the opportunity was more by chance.

“This is why I call myself an accidental entrepreneur – because it was an accidental encounter with another entrepreneur… who wanted to set up shop in India and… asked me whether I would be able to partner this venture,” she says.

The chance meeting persuaded Ms Mazumdar-Shaw to launch into the business of developing and making enzymes.

She says she wasn’t daunted by the transition from brewery to biotech. “If you think about brewing, it is biotechnology. And I would say that I was a technologist at heart. So whether I… fermented beer or whether I fermented enzymes, the base technology was the same.”

Female entrepreneurs

Gradually she moved the business into manufacturing medicines. The original development and sale of enzymes gave her the cash flow to fund the research and production of pharmaceutical drugs.

She feels this was a canny business move.

“There was no venture funding in India, so it forced me to create a business model that was based on revenues and profits.”

She adds: “That got us into a very different kind of format… to the typical biotech format, which depends largely on VC [venture capitalist] funding.”

But she admits that even as a female entrepreneur she still had to contend with the old issue of gender prejudice.

“Banks were very fearful of lending to a woman because I was considered high risk.”

Her age and the relatively new area of biotechnology didn’t help matters: “I was young, I was twenty-five years old… banks were very nervous about lending to young entrepreneurs because they felt we didn’t have the business experience… and then I had… this strange business called biotechnology which no one understood.”

Kiran Mazumdar-Shaw says her previous experience of failure gave her the resilience to persevere.

Biocon, BangaloreBangalore has developed from a quiet city into South India’s technology hub

“I was determined to make a success of this business because I had failed to be a brew master,” she admits.

“I just kept knocking at people’s doors and I said ‘look you’ve got to… help me’. I did manage to persuade a few people to stand by me and fund me and that’s how I got the business started.”

Bangalore

Ms Mazumdar-Shaw started Biocon in 1978 when Bangalore had yet to become the hub of technology of South India.

She remembers it as a “sleepy old retired city” but says it was an exciting place to start experimenting.

“We were first generation entrepreneurs trying to start high technology businesses… whether it was IT and services, or whether it was my biotech business… that was a time where there was tremendous energy, you know, being unleashed.”

Now she says the transformation of Bangalore into a “vibrant high growth centre” reflects the paradox of India. She believes the contrast between high wealth and extreme poverty – often within a few kilometres of each other – is the result of a failure to follow an inclusive economic agenda.

Social Entrepreneurship

Aside from running Biocon, Kiran Mazumdar-Shaw has also undertaken some social entrepreneurship projects.

One area she’s become involved with is public health. “I am very concerned about the fact that India as a country does not have a national health system, and I am determined to try and influence the government to really build a national health system for the country,” she says.

In the meantime, she has created a network of small clinics to provide some basic health care in rural areas.

BIOCON

  • Turnover (2010): Rs 2400 Cr, approx 535 million US dollars
  • Number of employees: 5000
  • HQ Location: Bangalore
  • Year founded: 1978
  • Ownership: Listed on BSE & NSE (India)

It’s a part of a “micro health insurance programme” funded largely by her, with small donations from those using it.

Pick yourself up

Kiran Mazumdar-Shaw says self-confidence is an important factor in entrepreneurship.

“A can-do attitude” is essential because obstacles and difficulties are inevitable. “I’ve had many failures in terms of technological… business… and even research failures,” she explains.

“I really believe that entrepreneurship is about being able to face failure, manage failure and succeed after failing.”

The key is to be able to tell the difference between total failure and setbacks which can be overcome.

“I think in my particular case, I’ve seen that failures are not absolute. That you can build and modify those failures to succeed.”

 

Kiran Mazumdar-Shaw, chairman and managing director, Biocon.
Indian biopharma giant Biocon reported healthy growth of 22 percent for Q1 FY14 riding on the back of an increased geographical footprint in the emerging markets

Bangalore: Indian biopharma giant Biocon reported healthy growth of 22 percent for Q1 FY14. The firm clocked revenues worth $121 million (Rs723 crore), EBITDA of $29.50 million (Rs175 crore); and profit after tax (PAT) of $15.80 million (Rs94 crore).

Read more at: http://www.biospectrumasia.com/biospectrum/news/192549/how-biocon-clock-revenue-worth-usd121-mn#.UfdqX6I3CSo

Biocon’s India-focused branded formulations vertical as well as research services continue to grow at a steady pace

………
check this video

…..

Indian Pharma Market Needs Strong Regulatory Set-up: Kiran Mazumdar-Shaw


Kiran Mazumdar Shaw

Kiran Mazumdar-Shaw, MD, BIOCON

Indian Pharma Market Needs Strong Regulatory Set-up:   Kiran Mazumdar-Shaw, MD, BIOCON

Biocon is looking at gaining market share and improving its margins with a greater focus on its product mixes and organizational efficiencies. Biocon Chairman and Managing Director Kiran Mazumdar-Shaw tells Financial Express that the company has outpaced the market, despite various challenges and that the pharmaceutical market needs to have a more robust regulatory set-up. Edited excerpts:

READ ALL AT

http://kiranmazumdarshaw.blogspot.in/2013/07/indian-pharma-market-needs-strong.html

………………

Serum Institute of India acquires rights to TB vaccine


Serum Institute of India acquires rights to TB vaccine

Serum Institute of India, a Pune-based manufacturer of vaccines, is planning on taking a promising vaccine – originally developed in Germany – and introducing it into the clinic. Studies have shown that the new vaccine is more effective and better tolerated than currently available options.

By signing a contract with Hannover-based Vakzine Projekt Management (VPM), Serum has secured the licence to the various patents and technologies related to the…

Click here to read more

…..

Natural Remedies for Erectile Dysfunction (ED) & Impotence


WAIT FOR VIDEO TO LOAD

……………………………………

Indian Pharma Market Needs Strong Regulatory Set-up: Kiran Mazumdar-Shaw


DRUG REGULATORY AFFAIRS INTERNATIONAL

Kiran Mazumdar Shaw

Kiran Mazumdar-Shaw, MD, BIOCON

 

Indian Pharma Market Needs Strong Regulatory Set-up:   Kiran Mazumdar-Shaw, MD, BIOCON

 

Biocon is looking at gaining market share and improving its margins with a greater focus on its product mixes and organizational efficiencies. Biocon Chairman and Managing Director Kiran Mazumdar-Shaw tells Financial Express that the company has outpaced the market, despite various challenges and that the pharmaceutical market needs to have a more robust regulatory set-up. Edited excerpts:

READ ALL AT

http://kiranmazumdarshaw.blogspot.in/2013/07/indian-pharma-market-needs-strong.html

View original post

Watermelon Juice Prevents Aching Muscles Food Chemistry: The amino acid L-citrulline found in the fruit could help athletes avoid muscle soreness after a hard workout


Green Chemistry International

Photo of watermelon juice smoothie in tall glass
The Next Sports Drink?
Watermelon drinks, like this smoothie, could help cut down on muscle soreness after intense exercise.
Credit: Shutterstock
Before taking a long bike ride on a hot summer day, have some watermelon: The juicy fruit may ward off muscle pains. Researchers report that people who drank watermelon juice before exercising felt less sore the next day than those who drank a pink placebo beverage (J. Agric. Food Chem. 2013, DOI: 10.1021/jf400964r). They also found that cells absorb the presumed active ingredient, L-citrulline, more readily from unpasteurized watermelon juice than from plain water spiked with the compound, suggesting the natural source is the optimal delivery
medium.

View original post

India seeks to cancel Roche cancer patent


india-may-revoke-roche-s-breast-cancer-drug-s-patent-using-section-66-of-the-indian-patents-act

India may revoke Roche’s breast cancer drug’s patent using section 66 of the Indian Patents Act

http://www.biospectrumasia.com/biospectrum/news/192436/india-seeks-cancel-roche-cancer-patent#.UfXtuaI3CSo

India’s health ministry is looking to revoke Roche’s breast cancer drug’s patent in public interest using powers under section 66 of the Indian Patents Act India may revoke Roche’s breast cancer drug’s patent using section 66 of the Indian Patents Act Related Articles Oramed gets Japanese patent for protein delivery Cipla wins patent case against Roche Alchemia cancer drug gets US patent protection Alchemia gets US patent for oncology platform technology New Delhi: India’s health ministry has asked for a cancellation of patent to Roche’s breast cancer medicine Trastuzumab, using a rarest-of-the-rare provision in the Indian Patents Act.
Read more at: http://www.biospectrumasia.com/biospectrum/news/192436/india-seeks-cancel-roche-cancer-patent#.UfXtuaI3CSo

%d bloggers like this: